Revolution Medicines (NASDAQ:RVMD) CEO Mark Goldsmith outlined the company’s late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and offered updates on colorectal cancer and earlier-stage pipeline efforts during a conversation with Guggenheim Senior Biotech Analyst Michael Schmidt. Phase III RASolute 302: OS event-driven readout expected in 1H 2026 Goldsmith said […]